Xiangyu Medical Co. Ltd. A Net Assets
Xiangyu Medical Co. Ltd. A net assets. Based on the latest financial reports, Xiangyu Medical Co. Ltd. A (688626) has net assets worth CN¥2.04 Billion CNY (≈ $298.63 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.27 Billion ≈ $478.83 Million USD) and total liabilities (CN¥1.23 Billion ≈ $180.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 688626 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.04 Billion |
| % of Total Assets | 62.37% |
| Annual Growth Rate | 54.2% |
| 5-Year Change | 176.44% |
| 10-Year Change | N/A |
| Growth Volatility | 110.99 |
Net Assets of Xiangyu Medical Co. Ltd. A (2017–2024)
Net assets of Xiangyu Medical Co. Ltd. A from 2017 to 2024. This chart illustrates how Xiangyu Medical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See Xiangyu Medical Co. Ltd. A (688626) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Xiangyu Medical Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Xiangyu Medical Co. Ltd. A from 2017 to 2024. For live market cap and overall valuation, see Xiangyu Medical Co. Ltd. A stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.05 Billion ≈ $300.68 Million |
-2.50% |
| 2023-12-31 | CN¥2.11 Billion ≈ $308.38 Million |
+8.64% |
| 2022-12-31 | CN¥1.94 Billion ≈ $283.86 Million |
-0.29% |
| 2021-12-31 | CN¥1.95 Billion ≈ $284.70 Million |
+161.75% |
| 2020-12-31 | CN¥743.29 Million ≈ $108.77 Million |
+35.82% |
| 2019-12-31 | CN¥547.28 Million ≈ $80.08 Million |
+31.93% |
| 2018-12-31 | CN¥414.81 Million ≈ $60.70 Million |
+318.63% |
| 2017-12-31 | CN¥99.09 Million ≈ $14.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Xiangyu Medical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15155.0% over the analyzed period, indicating profitable operations and earnings retention.
Xiangyu Medical Co. Ltd. A Net Assets Breakdown (December 2024)
Xiangyu Medical Co. Ltd. A net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥676.04 Million | 33.16% |
| Common Stock | CN¥160.00 Million | 7.85% |
| Other Components | CN¥1.20 Billion | 58.99% |
| Total Equity | CN¥2.04 Billion | 100.00% |
Xiangyu Medical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Xiangyu Medical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Trican Well Service Ltd.
TO:TCW
|
$945.78 Million |
|
Hanmi Financial Corporation
NASDAQ:HAFC
|
$946.11 Million |
|
Daktronics Inc
NASDAQ:DAKT
|
$946.20 Million |
|
Jiangsu Seagull Cooling Tower
SHG:603269
|
$946.21 Million |
|
Svenska Handelsbanken AB (publ)
ST:SHB-B
|
$945.37 Million |
|
Sichuan Haite High-tech Co Ltd
SHE:002023
|
$945.35 Million |
|
Shenzhen SEG Co Ltd
SHE:000058
|
$945.29 Million |
|
Piraeus Port Authority S.A
AT:PPA
|
$945.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xiangyu Medical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,090,900,915 to 2,038,679,134, a change of -52,221,781 (-2.5%).
- Net income of 102,943,560 contributed positively to equity growth.
- Dividend payments of 85,590,792 reduced retained earnings.
- Share repurchases of 77,572,236 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥102.94 Million | +5.05% |
| Dividends Paid | CN¥85.59 Million | -4.2% |
| Share Repurchases | CN¥77.57 Million | -3.81% |
| Other Changes | CN¥8.00 Million | +0.39% |
| Total Change | CN¥- | -2.50% |
Book Value vs Market Value Analysis
This analysis compares Xiangyu Medical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 48.87x to 2.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.83 | CN¥40.39 | x |
| 2018-12-31 | CN¥3.46 | CN¥40.39 | x |
| 2019-12-31 | CN¥3.42 | CN¥40.39 | x |
| 2020-12-31 | CN¥4.65 | CN¥40.39 | x |
| 2021-12-31 | CN¥12.09 | CN¥40.39 | x |
| 2022-12-31 | CN¥12.14 | CN¥40.39 | x |
| 2023-12-31 | CN¥13.26 | CN¥40.39 | x |
| 2024-12-31 | CN¥13.66 | CN¥40.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xiangyu Medical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.05%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.85%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.44x
- Recent ROE (5.05%) is below the historical average (20.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 65.07% | 22.30% | 0.72x | 4.05x | CN¥54.57 Million |
| 2018 | 19.36% | 22.38% | 0.64x | 1.35x | CN¥38.85 Million |
| 2019 | 23.57% | 30.18% | 0.59x | 1.32x | CN¥74.25 Million |
| 2020 | 26.40% | 39.61% | 0.50x | 1.32x | CN¥121.91 Million |
| 2021 | 10.43% | 38.57% | 0.24x | 1.13x | CN¥8.39 Million |
| 2022 | 6.51% | 25.68% | 0.21x | 1.23x | CN¥-67.29 Million |
| 2023 | 10.86% | 30.50% | 0.29x | 1.24x | CN¥18.05 Million |
| 2024 | 5.05% | 13.85% | 0.25x | 1.44x | CN¥-100.92 Million |
Industry Comparison
This section compares Xiangyu Medical Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,256,024,119
- Average return on equity (ROE) among peers: 25.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xiangyu Medical Co. Ltd. A (688626) | CN¥2.04 Billion | 65.07% | 0.60x | $945.65 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $5.13 Billion | 16.57% | 0.36x | $384.61 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $4.24 Billion |
| Double Medical Technology Inc (002901) | $1.46 Billion | 25.48% | 0.14x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $2.85 Billion | 49.59% | 0.20x | $494.04 Million |
| Lepu Medical Tech Beijing (300003) | $511.23 Million | 39.39% | 0.19x | $3.40 Billion |
| INKON Life Technology Co Ltd (300143) | $81.55 Million | 14.06% | 1.01x | $817.03 Million |
| Edan Instruments Inc (300206) | $217.47 Million | 30.36% | 0.22x | $1.02 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $505.98 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $83.90 Million | 31.18% | 0.36x | $473.66 Million |
| Sinocare Inc (300298) | $1.24 Billion | 11.58% | 0.08x | $1.56 Billion |
About Xiangyu Medical Co. Ltd. A
Xiangyu Medical Co.,Ltd engages in the research and development, manufacture, and marketing of rehabilitation and physiotherapy equipment in China. It provides various therapy such as smart occupational, electro, sport, rehab, cold and heat, gait training device, hydrotherapy, air compression, phototherapy, traction table, magnetic, CPM, occupational, shock wave and ultrasound, massage, treatment… Read more